Letters to the Editor

High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial

Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Texas Children's Hospital, Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine and Dan L. Duncan Cancer Center, Houston, TX
Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and The Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA
Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN
Division of Hematology, Oncology, BMT, and Cellular Therapies, Seattle Children’s Hospital, Seattle, WA
Princess Máxima Center of Pediatric Oncology, Utrecht, The Netherlands; Emma Children’s Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Amsterdam Rheumatology and Immunology Center, Cancer Center Amsterdam, Amsterdam UMC, location Vrije Universiteit, Amsterdam
Texas Children's Hospital, Department of Pediatrics, Division of Hematology/Oncology, Baylor College of Medicine and Dan L. Duncan Cancer Center, Houston, TX
Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam
Haematologica Early view Jan 30, 2025 https://doi.org/10.3324/haematol.2024.286171